Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Autologous Platelet-rich Plasma With Hyaluronic Acid for the Treatment of Osteoarthritis of the Knee Joint

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with osteoarthritis of knee (by American College of Rheumatology Criteria) and Kellgren-Lawrence grade I \~ III~* More than 40 out of 100-mm VAS scale for pain at screening and baseline~* Participant is willing and able to give informed consent for participation in the study~Exclusion Criteria:~* Patients with Hb values \< 10 g/dl and platelet values \< 100,000/ul~* Patients with a current or medical history of autoimmune disease~* Recent fever ( within 2 weeks) or serious illness~* Local infection at the site of the procedure~* Corticosteroid injection at treatment site within 1 month~* Systematic use of corticosteroids within 2 weeks~* Female participants who are pregnant, lactating or planning pregnancy during the course of the study~* Patients who have been administered with immunosuppressants within the past 6 weeks~* Patients who are enrolled in any other clinical trials within 4 weeks~* Patients who the principal investigator considers inappropriate for participation in the clinical trial for reasons other than those listed above

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PRP group (Type: EXPERIMENTAL): Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
- Hyaloronan group (Type: ACTIVE_COMPARATOR): Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).